Compare RES & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RES | CAPR |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1995 | 2011 |
| Metric | RES | CAPR |
|---|---|---|
| Price | $6.95 | $28.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $5.64 | ★ $44.63 |
| AVG Volume (30 Days) | ★ 2.2M | 1.0M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,919,000,000.00 | N/A |
| Revenue This Year | $3.29 | N/A |
| Revenue Next Year | $4.05 | $3.31 |
| P/E Ratio | $45.40 | ★ N/A |
| Revenue Growth | ★ 2216.21 | N/A |
| 52 Week Low | $4.18 | $4.30 |
| 52 Week High | $8.16 | $40.37 |
| Indicator | RES | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 38.69 |
| Support Level | $6.42 | $28.45 |
| Resistance Level | $7.41 | $30.06 |
| Average True Range (ATR) | 0.27 | 2.08 |
| MACD | -0.11 | -0.63 |
| Stochastic Oscillator | 10.32 | 2.36 |
RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. Its operating segment includes Technical Services and Support Services. The Technical Services segment, which generates maximum revenue, comprises service lines that generate revenue based on equipment, personnel, or materials at the well site and are closely aligned with completion and production activities of the customers. The Support Services segment comprises service lines that generate revenue from services and equipment offered off the well site and are closely aligned with the customers' drilling activities.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.